FR EN
Share this page

Team

WP0 – Coordination

 

Pr. Denis Bertin

Aix-Marseille Université
Deputy Chairman of the Foundation A*Midex

Contact

 

Pr. Fabrice Barlesi

Aix-Marseille Université, Institut Gustave Roussy
Coordinator of the PIONeeR Project RHU

Contact

 

Dr. Marie Roumieux

Aix-Marseille Université
RHU Project Manager
Administration of the consortium, management of the RHU
(scientific-regulatory-budgetary aspects, human resources),
communication and dissemination in connection with
the consortium and ATCG-Partners

Contact

 

WP1 – Clinical Studies

 

Dr. Pascale Tomasini

Aix-Marseille Université, AP-HM
Investigational clinical center of Marseille
Principal investigator-study coordinator of
the early phase randomized umbrella clinical trial

WP1 co-leader

Contact

 

Pr. Laurent Greillier

Aix-Marseille Université, AP-HM
Investigational clinical center of Marseille (and satellite centers)
Principal investigator-study coordinator of the biomarkers protocol

WP1 co-leader

Contact

 

Alexandra Giuliani

DRS APHM – Sponsor
Project manager of the two PIONeeR clinical studies
(regulatory documents, budget, logistics and human resources)

Contact

 

Dr. Maryannick Le Ray

DRS APHM – Sponsor
CRA-coordinator
Redaction of regulatory documents, patients
(inclusions, e-CRF)
& samples follow-up in connection with academic
and industrial analysis platforms

Contact

 

Pr. Julien Mazières

Hôpitaux de Toulouse-Université Paul Sabatier
Investigational clinical center of the Toulouse University Hospital (and satellite centers)
Co-principal investigator of the biomarkers protocol and
of the early phase randomized umbrella clinical trial

Contact

 

Dr. Maurice Pérol

Centre Léon Bérard (CLB)
Investigational clinical center of the CLB Lyon (and satellite centers)
Co-principal investigator of the biomarkers protocol and of
the early phase randomized umbrella clinical trial

Contact

 

Dr. Nicolas Ozan

AstraZeneca
Medical Director Oncology France
Link between AZ teams in the US & the UK, and the AP-HM
and RHU coordination teams (supply, regulatory and legal aspects of experimental molecules)

Contact

 

Dr. David Perol

Centre Léon Bérard (CLB)
Clinical Research and Innovation Department
Study design and statistical analysis of the
early phase randomized umbrella clinical trial

Contact 

 

WP2 – Biomarkers

 

Dr. Jacques Fieschi

Veracyte
WP2 leader

Contact

 

Dr. Florence Monville

Veracyte
Coordinator of the Biomarkers profiling program (blood, tumors, feces)

Contact

 

Dr. Vanina Leca

Veracyte
Biomarkers profiling program (blood, tumors, feces)

Contact

 

Dr. Loïc Juquel

Aix-Marseille Université, AP-HM
APHM anatomopathology department
Centralized collection and processing of
tumor samples from the PIONeeR protocols

Contact

 

Dr. Frédéric Vély

Aix-Marseille Université, AP-HM
MI/AP-HM immuno-profiling platform
Immunoprofiling of soluble and cellular biomarkers
from PIONeeR patient blood samples

Contact

 

Pr. Florence Sabatier

Aix Marseille Université AP-HM
Vasculo-monitoring platform of APHM
Study of the link between immunotherapy and
the endothelial compartment in PIONeeR patients

Contact

 

Laurent Arnaud

Engineer – AP-HM
Vasculo-monitoring platform of APHM
Study of the link between immunotherapy and
the endothelial compartment in PIONeeR patients

Contact

 

Pr. Joseph Ciccolini

Aix-Marseille Université, APHM
Centre de Recherche en Cancérologie de Marseille (CRCM)- SMARTc laboratory
Clinical pharmacokinetics and toxicology department
PK-PD study and modeling

Contact

 

Dr. Mourad Hamimed

Aix-Marseille Université- SMARTc laboratory (CRCM)
Engineer
Mathematical modeling of the efficacy-toxicity balance
of anti-PD (L)1 based on PK-PD studies in PIONeeR patients

Contact

 

Dr. Sivan Bokobza

Manager IHC, Innate Pharma
Tissue biomarkers profiling by immuno-histochemistry

Contact

 

Dr Sébastien Benzekry 

Inria – Inserm team COMPO (CRCM)
Biostatistician
Biostatistical, integrative (machine learning)
and mechanistic analyses of the PIONeeR BioMarkers protocol and
mathematical modeling of the response to immunotherapies

Contact

 

WP3 – New immune-checkpoint modulators candidates

 

Pr. Eric Vivier

Aix-Marseille Université, APHM,
Centre d’Immunologie de Marseille Luminy (CIML), Innate Pharma

WP3 co-leader

Contact

 

Dr. Cathy Laporte

Innate Pharma
Scientific and administrative coordination

Contact

 

Dr. Pierre Milpied

Inserm, Centre d’Immunologie de Marseille Luminy (CIML)
Characterization of anti-tumor activity of B lymphocytes

WP3 co-leader

Contact

 

Dr. Emilie Narni-Mancinelli

Inserm, Centre d’Immunologie de Marseille Luminy (CIML)
Evaluation of the NKP44/46 pathway in anti-tumor immunity

Contact

 

Pr. Daniel Olive

Aix-Marseille Université, IPC, CRCM
Evaluation of the BTLA/HVEM pathway in anti-tumor immunity

WP3 co-leader

Contact

 

Dr. Emmanuel Valentin

ImCheck Therapeutics
Evaluation of the BTLA/HVEM pathway in anti-tumor immunity

Contact

 

Dr. Ana Zarubica

CIPHE platform
Evaluation of the BTLA/HVEM pathway in anti-tumor immunity
Generation and immunophenotyping of transgenic mouse models

Contact

 

Pr. François Romagné

Aix-Marseille Université, MImAbs
Monoclonal antibody engineering and in vitro &
in vivo immuno-pharmacology

Contact

 

WP4 – Communication and exploitation

 

Dr. Jean Philippe Tissier-Seta
Céline Voisin
Marie Puvieux

ATCG-Partners
Scientific communication and dissemination

jpts@atcg-partners.com
cv@atcg-partners.com
mp@atcg-partners.com